Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.

de Lucena D, Fernandes BS, Berk M, Dodd S, Medeiros DW, Pedrini M, Kunz M, Gomes FA, Giglio LF, Lobato MI, Belmonte-de-Abreu PS, Gama CS.

J Clin Psychiatry. 2009 Oct;70(10):1416-23. doi: 10.4088/JCP.08m04935gry. Erratum in: J Clin Psychiatry. 2011 Aug;72(8):1157.

PMID:
19906345
2.

A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia.

Lieberman JA, Papadakis K, Csernansky J, Litman R, Volavka J, Jia XD, Gage A; MEM-MD-29 Study Group.

Neuropsychopharmacology. 2009 Apr;34(5):1322-9. doi: 10.1038/npp.2008.200. Epub 2008 Nov 12.

3.

Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study.

Krivoy A, Weizman A, Laor L, Hellinger N, Zemishlany Z, Fischel T.

Eur Neuropsychopharmacol. 2008 Feb;18(2):117-21. Epub 2007 Aug 28.

PMID:
17728110
5.

Molecular targets for treating cognitive dysfunction in schizophrenia.

Gray JA, Roth BL.

Schizophr Bull. 2007 Sep;33(5):1100-19. Epub 2007 Jul 7. Review.

7.

Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.

Peskind ER, Potkin SG, Pomara N, Ott BR, Graham SM, Olin JT, McDonald S.

Am J Geriatr Psychiatry. 2006 Aug;14(8):704-15.

PMID:
16861375
8.
9.

[Memantine as an adjunctive therapy for schizophrenia negative symptoms].

Gama CS, Antunes P, Moser C, Belmonte-de-Abreu PS.

Rev Bras Psiquiatr. 2005 Sep;27(3):257-8. Epub 2005 Oct 4. Portuguese. No abstract available.

10.

A double-blind, cross-over comparison of the effects of amantadine or placebo on visuomotor and cognitive function in medicated schizophrenia patients.

Silver H, Goodman C, Isakov V, Knoll G, Modai I.

Int Clin Psychopharmacol. 2005 Nov;20(6):319-26.

PMID:
16192841
11.

Clinical application of the concept of relative potency: an example involving chlorpromazine and haloperidol.

Preskorn SH.

J Psychiatr Pract. 2005 Jul;11(4):258-61. No abstract available.

PMID:
16041236
12.

Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms.

Sacco KA, Termine A, Seyal A, Dudas MM, Vessicchio JC, Krishnan-Sarin S, Jatlow PI, Wexler BE, George TP.

Arch Gen Psychiatry. 2005 Jun;62(6):649-59.

PMID:
15939842
13.

A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia.

Woodward ND, Purdon SE, Meltzer HY, Zald DH.

Int J Neuropsychopharmacol. 2005 Sep;8(3):457-72. Epub 2005 Mar 23. Review.

PMID:
15784157
14.

N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives.

Millan MJ.

Psychopharmacology (Berl). 2005 Apr;179(1):30-53. Epub 2005 Mar 10. Review.

PMID:
15761697
15.

Memantine as a neuroprotective treatment in schizophrenia.

Rands GS.

Br J Psychiatry. 2005 Jan;186:77; author reply 77-8. No abstract available.

16.

LTP and LTD: an embarrassment of riches.

Malenka RC, Bear MF.

Neuron. 2004 Sep 30;44(1):5-21. Review.

18.

Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists.

Friedman JI.

Psychopharmacology (Berl). 2004 Jun;174(1):45-53. Epub 2004 Feb 19. Review.

PMID:
15205878
19.
20.

Supplemental Content

Support Center